On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”) due to liquidity concerns. CNS Pharmaceuticals … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the company’s ongoing global trial. The potentially pivotal trial is focused on evaluating Berubicin for the treatment … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that enrollment is continuing in its ongoing global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). Specifically, the company is reporting that it has enrolled the first … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Spain in Key Global Trial Studying Berubicin for Treatment of GBM”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently reported that 67 patients have enrolled in the potentially pivotal phase 2 globally cited clinical study comparing drug candidate Berubicin’s effectiveness to second-line standard-of-care chemotherapy drug Lomustine. “The  company plans to have more than 200 patients participate in the clinical trial on a 2:1 randomization schema between those receiving Berubicin … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Pleased with Early Results from Global Clinical Trial”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, is enrolling patients in a phase 2 trial to evaluate the efficacy of its flagship drug candidate. The potentially pivotal trial will evaluate Berubicin for the treatment of glioblastoma multiforme … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses ‘Lifeblood’ of Phase 2 Berubicin Trial”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated phase 1b /2 trial evaluating the company’s novel anthracycline, Berubicin. The study, titled “Evaluation of the safety and efficacy of Berubicin in the treatment of … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin to Be Evaluated in Investigator-Initiated Phase 1b/2 Trial”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat glioblastoma multiforme (“GBM”), a common and one of the most aggressive primary brain cancers. “The drug, Berubicin, is an anthracycline chemotherapy agent … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Poised to Potentially Change History”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the Virtual Investor 2023 “Companies to Watch” event. Climaco’s presentation is scheduled to take … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Strategic Board Appointment of Faith L. Charles, JD

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Faith L. Charles as chair of its board of directors. Since 2010, Charles has served as a corporate transactions and securities partner at the … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Strategic Board Appointment of Faith L. Charles, JD”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial

A Phase 2, globally sited clinical trial evaluating the potential efficacy of a promising brain cancer drug candidate against deadly glioblastoma (“GBM”) tumors is proceeding apace with a variety of patient profiles, affirming the drug developer’s confidence in its product.  In a Dec. 8 news release, CNS Pharmaceuticals (NASDAQ: CNSP) reported that 67 patients have … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial”

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered